Showing results (81-90 of 118) with videos related to
Sort By:
Pageof 12
Cancers|May 14, 2022
Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA)Markus Joerger, Yannis Metaxas, Khalil Zaman, et al.European Journal of Cancer (Oxford, England : 1990)|November 19, 2011
Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03)Gianfranco A Pesce, Dirk Klingbiel, Karin Ribi, et al.The Lancet. Oncology|July 17, 2009
Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trialRoger Stupp, Michael Mayer, Roger Kann, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 14, 2020
Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14)Solange Peters, Enriqueta Felip, Urania Dafni, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2003
Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trialDaniel C Betticher, Shu-Fang Hsu Schmitz, Martin Tötsch, et al.Cancer Immunology, Immunotherapy : CII|March 8, 2020
Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapyTali Voloshin, Noa Kaynan, Shiri Davidi, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 30, 2018
Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01)Martin Früh, Daniel C Betticher, Roger Stupp, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2004
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapyNasser Hanna, Frances A Shepherd, Frank V Fossella, et al.Clinical Lung Cancer|April 7, 2015
Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09Oliver Gautschi, Nicholas Mach, Sacha I Rothschild, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 17, 2023
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With ChemotherapyNasser Hanna, Frances A Shepherd, Frank V Fossella, et al.Pageof 12